Is androgen therapy indicated in men with osteoporosis?

Joint Bone Spine

Volumn 80, Issue 5, 2013, Pages 459-465

  Hoppé, Emmanuel ^a   Bouvard, Béatrice ^a   Royer, Mathieu ^a   Chappard, Daniel ^a   Audran, Maurice ^a   Legrand, Erick ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Bone mineral density; Fracture; Male osteoporosis; Replacement therapy; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOPATCH; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG; VITAMIN D;

ACCIDENT PREVENTION; AGED; AGING; ANDROGEN REPLACEMENT THERAPY; ANDROGEN THERAPY; APPLICATION SITE IRRITATION; BODY FAT; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CANCER RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COGNITIVE DEFECT; COUGHING; DEPRESSION; DIET SUPPLEMENTATION; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOCRINOLOGIST; FALLING; FEMUR FRACTURE; FRACTURE; GERIATRIC PATIENT; GYNECOMASTIA; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LEAN BODY WEIGHT; LIVER TOXICITY; LUMBAR SPINE; MALE; MALE OSTEOPOROSIS; MEN'S HEALTH; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORTALITY; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OUTCOMES RESEARCH; PENIS ERECTION; PRACTICE GUIDELINE; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RISK; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDERED BREATHING; TESTOSTERONE BLOOD LEVEL;

BONE MINERAL DENSITY; FRACTURE; MALE OSTEOPOROSIS; REPLACEMENT THERAPY; TESTOSTERONE;

AGED; ANDROGENS; BONE DENSITY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 84885940139     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.03.002     Document Type: Short Survey

References (35)

1. Maravic M., Taupin P., Landais P., et al. Decrease of inpatient mortality for hip fracture in France. Joint Bone Spine 2011, 78:506-509.
2. Briot K., Cortet B., Trémollières F., et al. Male osteoporosis: diagnosis and fracture risk evaluation. Joint Bone Spine 2009, 76:129-133.
3. Hoppé E., Morel G., Biver E., et al. Male osteoporosis: do sex steroids really benefit bone health in men?. Joint Bone Spine 2011, 78:S191-S196.
4. Tracz M.J., Sideras K., Boloña E.R., et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006, 91:2011-2016.
5. Amory J.K., Watts N.B., Easley K.A., et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004, 89:503-510.
6. Nair K.S., Rizza R.A., O'Brien P., et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006, 355:1647-1659.
7. Merza Z., Blumsohn A., Mah P.M., et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 2006, 29:381-391.
8. Emmelot-Vonk M.H., Verhaar H.J., Nakhai Pour H.R., et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008, 299:39-52. [Erratum in: JAMA 2008;299(6):634].
9. Svartberg J., Agledahl I., Figenschau Y., et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008, 20:378-387.
10. Basurto L., Zarate A., Gomez R., et al. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male 2008, 11:140-145.
11. Kenny A.M., Kleppinger A., Annis K., et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010, 58:1134-1143.
12. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on bone mineral density in men over 65years of age. J Clin Endocrinol Metab 1999, 84:1966-1972.
13. Kenny A.M., Prestwood K.M., Gruman C.A., et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001, 56:M266-M272.
14. Hall G.M., Larbre J.P., Spector T.D., et al. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 1996, 35:568-573.
15. Reid I.R., Wattie D.J., Evans M.C., et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996, 156:1173-1177.
16. Crawford B.A., Liu P.Y., Kean M.T., et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003, 88:3167-3176.
17. Isidori A.M., Giannetta E., Greco E.A., et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005, 63:280-293.
18. Haddad R.M., Kennedy C.C., Caples S.M., et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:29-39.
19. Boloña E.R., Uraga M.V., Haddad R.M., et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:20-28.
20. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:2536-2559.
21. Bhasin S., Calof O.M., Storer T.W., et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006, 2:146-159.
22. Calof O.M., Singh A.B., Lee M.L., et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005, 60:1451-1457.
23. Fernández-Balsells M.M., Murad M.H., Lane M., et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 6:2560-2575.
24. Corona G., Rastrelli G., Morelli A., et al. Hypogonadism and metabolic syndrome. J Endocrinol Invest 2011, 34:557-567.
25. Hoppé E., Bouvard B., Royer M., et al. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine 2010, 77:306-312.
26. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
27. Arrêté du 16 décembre 2002. http://www.agmed.sante.gouv.fr/htm/pharma/add.58.pdf.
28. Villareal D.T., Holloszy J.O., Kohrt W.M. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) 2000, 53:561-568.
29. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999, 84:3459-3462.
30. Gao W., Reiser P.J., Coss C.C., et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005, 146:4887-4897.
31. Narayanan R., Coss C.C., Yepuru M., et al. Steroidal androgens and non-steroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008, 22:2448-2465.
32. Haendler B., Cleve A. Recent developments in anti-androgens and selective androgen receptor modulators. Mol Cell Endocrinol 2012, 352:79-91.
33. Howell S.J., Radford J.A., Adams J.E., et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 2001, 55:315-324.
34. Christmas C., O'Connor K.G., Harman S.M., et al. Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J Gerontol A Biol Sci Med Sci 2002, 57:M12-M18.
35. Guide des analyses spécialisées 2007. 5e édition. P361. Laboratoires Pasteur Cerba. Édition Elsevier.